Skip to main content

Optimization of PD-L1 algorithm for predicting overall survival (OS) in patients with urothelial cancer (UC) treated with durvalumab monotherapy

7 stars
Zajac
Magdalena
Oncology Companion Diagnostics Unit, Precision Medicine and Genomics, IMED Biotech Unit
AstraZeneca
Cambridge
United Kingdom
Show all authors
Ye
Jiabu
AstraZeneca
Cambridge
United Kingdom
Mukhopadhyay
Pralay
AstraZeneca
Gaithersburg
United States
Ben
Yong
AstraZeneca
Gaithersburg
United States
Antal
Joyce
MedImmune
Gaithersburg
United States
Gupta
Ashok K
MedImmune
Gaithersburg
United States
Rebelatto
Marlon C
MedImmune
Gaithersburg
United States
Williams
J. Andrew
AstraZeneca
Cambridge
United Kingdom
Walker
Jill
AstraZeneca
Cambridge
United Kingdom

Tabs

Speciality: 
Oncology (medical)
Keywords: 
durvalumab, PD-L1, PD-L1 algorithm, Urothelial cancer, immune-oncology, Biomarker